https://www.selleckchem.com/products/ABT-263.html
Serum sICAM-1 levels were markedly higher in stage III/IV than stage I/II (SMD 1.96, 95% CI 1.08-2.84, P 0.001), Additionally, lung cancer patients with lymph node metastasis had a higher concentrations of serum sICAM-1(SMD 1.83, 95% CI 0.95-2.72, P 0.001), as well as with distant metastasis (SMD 0.86, 95% CI 0.47-1.25, P 0.001). Additionally, patients with higher sICAM-1 levels were related to a significantly poorer prognosis (progression free survival HR 1.16, 95% CI 1.07-1.26, P 0.001; overall survival HR 1.45, 95
Like
Comment
Share
